US biotech firm Moderna on Monday reported "positive interim" results in the first clinical tests of its vaccine against the new coronavirus performed on a small number of volunteers.
The vaccine appeared to produce an immune response in eight people who received it, of the same amplitude as that observed in people infected with the virus, the company said, adding that phase 3 trials with a large number of volunteers would begin in July.
Disclaimer: No Business Standard Journalist was involved in creation of this content
